FGF-2 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Suramin sodium is a highly charged polysulfonated compound that interacts intricately with fibroblast growth factor-2 (FGF-2). Its extensive sulfonate groups facilitate robust ionic interactions with target proteins, leading to conformational changes that can influence FGF-2's stability and activity. Additionally, Suramin sodium can alter the kinetics of ligand-receptor interactions, potentially impacting the efficiency of signaling pathways. Its exceptional solubility in water further promotes its reactivity in various biochemical contexts. | ||||||
PD 166866 | 192705-79-6 | sc-208154 | 5 mg | $300.00 | 1 | |
PD 166866 is a selective compound that modulates fibroblast growth factor-2 (FGF-2) through unique hydrophobic interactions and specific binding affinities. Its structure allows for the stabilization of FGF-2, enhancing its dimerization and subsequent receptor engagement. The compound's kinetic profile reveals a rapid association with FGF-2, influencing downstream signaling cascades. Additionally, PD 166866 exhibits distinct solubility characteristics, facilitating its interaction in diverse biological environments. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is a potent and selective FGFR inhibitor that directly targets the tyrosine kinase domain, preventing autophosphorylation and downstream signaling. By inhibiting FGFR, PD173074 disrupts FGF-2-mediated pathways, impeding cellular processes regulated by FGF-2 such as proliferation and angiogenesis. | ||||||
SU 5402 | 215543-92-3 | sc-204308 sc-204308A | 1 mg 5 mg | $63.00 $98.00 | 36 | |
SU5402 is a small molecule inhibitor of FGFR tyrosine kinase activity. It interferes with the ATP-binding site of FGFR, preventing autophosphorylation and downstream signaling. Through direct inhibition of FGFR, SU5402 disrupts FGF-2-mediated pathways, impacting cellular responses related to cell growth, differentiation, and angiogenesis. | ||||||
AZD4547 | 1035270-39-3 | sc-364421 sc-364421A | 5 mg 10 mg | $198.00 $309.00 | 6 | |
AZD4547 is a selective FGFR inhibitor that hinders FGFR autophosphorylation and downstream signaling. By targeting the kinase domain, AZD4547 directly inhibits FGFR, disrupting FGF-2-mediated cellular processes including proliferation and angiogenesis. This compound represents a specific approach to modulating FGF-2 activity by targeting the FGFR signaling pathway. | ||||||
BGJ398 | 872511-34-7 | sc-364430 sc-364430A sc-364430B sc-364430C | 5 mg 10 mg 50 mg 100 mg | $216.00 $252.00 $594.00 $1009.00 | 4 | |
BGJ398 is an active inhibitor of FGFR tyrosine kinases. By binding to the ATP-binding pocket of FGFR, it prevents autophosphorylation and downstream signaling. BGJ398 directly inhibits FGFR, disrupting FGF-2-mediated pathways and cellular responses related to cell proliferation and angiogenesis. This compound offers a targeted strategy for modulating FGF-2 activity through FGFR inhibition. | ||||||
Erdafitinib | 1346242-81-6 | sc-507388 | 10 mg | $138.00 | ||
JNJ-42756493 is a potent and selective FGFR inhibitor that interferes with the tyrosine kinase domain, preventing autophosphorylation and downstream signaling. By directly inhibiting FGFR, JNJ-42756493 disrupts FGF-2-mediated pathways, influencing cellular processes such as proliferation and angiogenesis. This compound represents a targeted strategy for modulating FGF-2 activity through FGFR inhibition. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
AP 24534 (Ponatinib) is a multi-tyrosine kinase inhibitor that includes FGFR among its targets. By inhibiting FGFR, Ponatinib interferes with FGF-2-mediated signaling pathways, impacting cellular responses related to proliferation and angiogenesis. This compound offers a broad yet specific approach to modulating FGF-2 activity by targeting multiple tyrosine kinases, including FGFR. | ||||||
Debio-1347 | 1265229-25-1 | sc-507386 | 10 mg | $324.00 | ||
Debio 1347 is a selective FGFR inhibitor that targets the ATP-binding site of FGFR, inhibiting autophosphorylation and downstream signaling. By directly inhibiting FGFR, Debio 1347 disrupts FGF-2-mediated pathways, influencing cellular processes such as proliferation and angiogenesis. This compound provides a specific means to modulate FGF-2 activity by interfering with FGFR signaling. | ||||||
JNJ-26481585 | 875320-29-9 | sc-364515 sc-364515A | 5 mg 50 mg | $321.00 $1224.00 | ||
JNJ-26481585 is an active inhibitor of FGFR tyrosine kinase activity. By binding to the ATP-binding site, it inhibits autophosphorylation and downstream signaling. JNJ-26481585 directly targets FGFR, disrupting FGF-2-mediated pathways and cellular responses related to cell growth and angiogenesis. This compound offers a specific approach to modulating FGF-2 activity through the inhibition of FGFR signaling. | ||||||